Britain's Oxford BioMedica has agreed with AstraZeneca AZN.L to manufacture the drugmaker's experimental COVID-19 vaccine, the cell therapy company said on Thursday.

Oxford BioMedica will provide the drugmaker with multiple batches of the vaccine, called AZD1222, under a one-year clinical and commercial supply agreement, the company said, adding that the majority of it is expected be produced throughout 2020.

Oxford BioMedica shares were up 7.3% at 769 pence after the announcement.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Shinjini Ganguli) ((Pushkala.A@thomsonreuters.com; Twitter: @pullthekart; within UK: +44 20 7542 1810, outside UK: +91 80 6182 2600; Mobile: +91 852 751 3793 ;))